An orally bioavailable inhibitor of ACAT (IC50s = 24 and 9.2 μM for ACAT1 and ACAT2, respectively) that reduces plasma total triglyceride and VLDL cholesterol levels in cholesterol-fed animal models; also used to decrease amyloid β generation in models of Alzheimer's disease